Compare Organon & Co. Common Stock (OGN) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Stryker Corporation — how do they compare? Organon & Co. Common Stock trades at $13.77 (market cap $3.61B), while Stryker Corporation trades at $290.92 (market cap $108.02B). The key difference: Stryker Corporation is far larger — about 29.9× Organon & Co. Common Stock's market cap, and Stryker Corporation pays the higher dividend (1.25%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| OGN | SYK | |
|---|---|---|
Market Cap | $3.61B | $108.02B |
Volume | 1,808,049 | 2,222,698 |
Sector | Health | Health |
52-Week High | $13.81 | $388.35 |
52-Week Low | $5.70 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $11.03B | $119.49B |
Dividend Yield | 0.58% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Stryker (SYK) trades at $290.84, up 2.9% on the day, with a bullish technical signal and strong analyst support. The company demonstrates robust fundamentals with a 14.43% net income margin and 16.51% ROE, though a recent earnings miss in Q1 2026 and ongoing legal scrutiny present headwinds. Cash flow improved significantly in 2026, and the upcoming Q3 2026 earnings report on October 29, 2026, is a key near-term catalyst.
The investment outlook is positive, supported by a consensus price target of $365.89 and no sell ratings among 52 analysts. However, risks include persistent manufacturing issues highlighted in recent news and potential securities law investigations. The stock's valuation at a P/E of 29.18 requires continued earnings growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
